FormWeb • emtricitabine-rilpivirine-tenofovir disoproxil fumarate

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

emtricitabine-rilpivirine-tenofovir disoproxil fumarate

emtricitabine-rilpivirine-tenofovir disoproxil fumarate

Non-formulary AIDS Drugs Formulary
Therapeutic Interchange

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Complera	TABLET, ORAL	200 mg-25 mg-300 mg

Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

emtricitabine-rilpivirine-tenofovir disoproxil fumarate (Complera)

200 mg-25 mg-300 mg tablet oral

emtricitabine (Emtriva) AND rilpivirine (Edurant) AND tenofovir disoproxil fumarate (Viread)

ONE 200 mg emtricitabine capsule oral PLUS ONE 25 mg rilpivirine tablet oral PLUS ONE 300 mg tenofovir disoproxil fumarate tablet oral

Dispense individual components separately

Reviewed: September 27, 2011

Last updated: Dec. 20, 2017

Black Box Warning: Lactic Acidosis; Severe Hepatomegaly; hepB co-infection

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.